Effect of metformin and statin use on survival in pancreatic cancer patients: A systematic literature review and meta-analysis

E. Jian-Yu, Judith Graber, Shou-En Lu, Yong Lin, Grace Lu-Yao, Xianglin Tan

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Background and Objective: Current epidemiological studies report conflicting results for the effect of statin or metformin on pancreatic cancer overall survival. This literature review and meta-analysis summarize the studies reporting an association between statin or metformin use and overall survival of pancreatic cancer patients. Methods: We systematically searched for studies about the association between statin or metformin use and pancreatic cancer overall survival in electronic databases (PubMed, ISI Web of Science, MEDLINE, Cochrane, Scopus, Google Scholar). A meta-analysis based on hazard ratios (HRs) and 95% confidence intervals (CIs) was performed using random effect models. Heterogeneity between the studies was examined using I2 statistics, and sensitivity analyses were conducted to assess the robustness of the findings. Results: Of 116 statin-related articles identified, 6 retrospective cohort studies representing 12,057 patients were included. There was significant heterogeneity between studies. Statin use was associated with improved survival among pancreatic cancer patients (meta-HR = 0.75; 95% CI: 0.59, 0.90; P < 0.001). Of 311 metformin-related articles, 8 retrospective cohort studies and 2 randomized clinical trials, representing 3,042 patients were identified. Metformin use was associated with better overall survival among pancreatic cancer patients (meta-HR = 0.79; 95% CI: 0.70, 0.92, P < 0.001), and significant heterogeneity was observed between studies. Conclusion: Our findings suggest that the improved survival time of pancreatic cancer patients are associated with statin or metformin use. Due to the multiple sources of heterogeneity of the original studies, these findings should be considered cautiously, and confirmed with larger prospective individual-level studies.

Original languageEnglish (US)
Pages (from-to)2595-2607
Number of pages13
JournalCurrent Medicinal Chemistry
Volume25
Issue number22
DOIs
StatePublished - Jan 1 2018

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Metformin
Pancreatic Neoplasms
Meta-Analysis
Survival
Hazards
Confidence Intervals
Cohort Studies
Retrospective Studies
PubMed
MEDLINE
Epidemiologic Studies
Randomized Controlled Trials
Statistics
Databases

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Molecular Medicine
  • Biochemistry
  • Pharmacology
  • Organic Chemistry

Keywords

  • Cancer drug
  • Meta-analysis
  • Metformin
  • Overall survival
  • Pancreatic cancer
  • Statin

Cite this

@article{f91ff8b30ff5453dbda77874c750db8d,
title = "Effect of metformin and statin use on survival in pancreatic cancer patients: A systematic literature review and meta-analysis",
abstract = "Background and Objective: Current epidemiological studies report conflicting results for the effect of statin or metformin on pancreatic cancer overall survival. This literature review and meta-analysis summarize the studies reporting an association between statin or metformin use and overall survival of pancreatic cancer patients. Methods: We systematically searched for studies about the association between statin or metformin use and pancreatic cancer overall survival in electronic databases (PubMed, ISI Web of Science, MEDLINE, Cochrane, Scopus, Google Scholar). A meta-analysis based on hazard ratios (HRs) and 95{\%} confidence intervals (CIs) was performed using random effect models. Heterogeneity between the studies was examined using I2 statistics, and sensitivity analyses were conducted to assess the robustness of the findings. Results: Of 116 statin-related articles identified, 6 retrospective cohort studies representing 12,057 patients were included. There was significant heterogeneity between studies. Statin use was associated with improved survival among pancreatic cancer patients (meta-HR = 0.75; 95{\%} CI: 0.59, 0.90; P < 0.001). Of 311 metformin-related articles, 8 retrospective cohort studies and 2 randomized clinical trials, representing 3,042 patients were identified. Metformin use was associated with better overall survival among pancreatic cancer patients (meta-HR = 0.79; 95{\%} CI: 0.70, 0.92, P < 0.001), and significant heterogeneity was observed between studies. Conclusion: Our findings suggest that the improved survival time of pancreatic cancer patients are associated with statin or metformin use. Due to the multiple sources of heterogeneity of the original studies, these findings should be considered cautiously, and confirmed with larger prospective individual-level studies.",
keywords = "Cancer drug, Meta-analysis, Metformin, Overall survival, Pancreatic cancer, Statin",
author = "E. Jian-Yu and Judith Graber and Shou-En Lu and Yong Lin and Grace Lu-Yao and Xianglin Tan",
year = "2018",
month = "1",
day = "1",
doi = "https://doi.org/10.2174/0929867324666170412145232",
language = "English (US)",
volume = "25",
pages = "2595--2607",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "22",

}

TY - JOUR

T1 - Effect of metformin and statin use on survival in pancreatic cancer patients

T2 - A systematic literature review and meta-analysis

AU - Jian-Yu, E.

AU - Graber, Judith

AU - Lu, Shou-En

AU - Lin, Yong

AU - Lu-Yao, Grace

AU - Tan, Xianglin

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background and Objective: Current epidemiological studies report conflicting results for the effect of statin or metformin on pancreatic cancer overall survival. This literature review and meta-analysis summarize the studies reporting an association between statin or metformin use and overall survival of pancreatic cancer patients. Methods: We systematically searched for studies about the association between statin or metformin use and pancreatic cancer overall survival in electronic databases (PubMed, ISI Web of Science, MEDLINE, Cochrane, Scopus, Google Scholar). A meta-analysis based on hazard ratios (HRs) and 95% confidence intervals (CIs) was performed using random effect models. Heterogeneity between the studies was examined using I2 statistics, and sensitivity analyses were conducted to assess the robustness of the findings. Results: Of 116 statin-related articles identified, 6 retrospective cohort studies representing 12,057 patients were included. There was significant heterogeneity between studies. Statin use was associated with improved survival among pancreatic cancer patients (meta-HR = 0.75; 95% CI: 0.59, 0.90; P < 0.001). Of 311 metformin-related articles, 8 retrospective cohort studies and 2 randomized clinical trials, representing 3,042 patients were identified. Metformin use was associated with better overall survival among pancreatic cancer patients (meta-HR = 0.79; 95% CI: 0.70, 0.92, P < 0.001), and significant heterogeneity was observed between studies. Conclusion: Our findings suggest that the improved survival time of pancreatic cancer patients are associated with statin or metformin use. Due to the multiple sources of heterogeneity of the original studies, these findings should be considered cautiously, and confirmed with larger prospective individual-level studies.

AB - Background and Objective: Current epidemiological studies report conflicting results for the effect of statin or metformin on pancreatic cancer overall survival. This literature review and meta-analysis summarize the studies reporting an association between statin or metformin use and overall survival of pancreatic cancer patients. Methods: We systematically searched for studies about the association between statin or metformin use and pancreatic cancer overall survival in electronic databases (PubMed, ISI Web of Science, MEDLINE, Cochrane, Scopus, Google Scholar). A meta-analysis based on hazard ratios (HRs) and 95% confidence intervals (CIs) was performed using random effect models. Heterogeneity between the studies was examined using I2 statistics, and sensitivity analyses were conducted to assess the robustness of the findings. Results: Of 116 statin-related articles identified, 6 retrospective cohort studies representing 12,057 patients were included. There was significant heterogeneity between studies. Statin use was associated with improved survival among pancreatic cancer patients (meta-HR = 0.75; 95% CI: 0.59, 0.90; P < 0.001). Of 311 metformin-related articles, 8 retrospective cohort studies and 2 randomized clinical trials, representing 3,042 patients were identified. Metformin use was associated with better overall survival among pancreatic cancer patients (meta-HR = 0.79; 95% CI: 0.70, 0.92, P < 0.001), and significant heterogeneity was observed between studies. Conclusion: Our findings suggest that the improved survival time of pancreatic cancer patients are associated with statin or metformin use. Due to the multiple sources of heterogeneity of the original studies, these findings should be considered cautiously, and confirmed with larger prospective individual-level studies.

KW - Cancer drug

KW - Meta-analysis

KW - Metformin

KW - Overall survival

KW - Pancreatic cancer

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=85026831102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026831102&partnerID=8YFLogxK

U2 - https://doi.org/10.2174/0929867324666170412145232

DO - https://doi.org/10.2174/0929867324666170412145232

M3 - Review article

C2 - 28403788

VL - 25

SP - 2595

EP - 2607

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 22

ER -